Tegafur[edit]

Tegafur is a chemotherapeutic agent and a prodrug to 5-FU, used in the treatment of various cancers. It is metabolized into 5-FU by CYP2A6, exerting its anticancer effects.

Overview[edit]

Classification: Chemotherapeutic agent, Fluorouracil prodrug
Specialty: Oncology
Mechanism of Action: Converted to 5-fluorouracil, inhibits thymidylate synthase
Administration: Oral
Metabolism: Primarily in the liver to 5-FU by CYP2A6

Medical Uses[edit]

As a prodrug to 5-FU, Tegafur is used in the treatment of the following cancers:<ref name = MD>

Martindale: The Complete Drug Reference(link). {{{website}}}. Pharmaceutical Press. 14 November 2011.

</ref>

Stomach (when combined with gimeracil and oteracil)
Breast (with uracil)
Gallbladder
Lung (specifically adenocarcinoma, typically with uracil)
Colorectal (usually when combined with gimeracil and oteracil)
Head and neck
Liver (with uracil)<ref>Ishikawa, T,

 Chemotherapy with enteric-coated tegafur/uracil for advanced hepatocellular carcinoma., 
 World Journal of Gastroenterology : WJG, 
 
 Vol. 14(Issue: 18),
 pp. 2797-2801,
 DOI: 10.3748/wjg.14.2797,
 PMID: 18473401,
 PMC: 2710718,
 
 Full text,</ref>

Pancreatic

It is often given in combination with drugs that alter its bioavailability and toxicity such as gimeracil, oteracil, or uracil.<ref name = MD/> These agents achieve this by inhibiting the enzyme dihydropyrimidine dehydrogenase (uracil/gimeracil) or orotate phosphoribosyltransferase (oteracil).<ref name = MD/>

Mechanism of Action[edit]

Tegafur is a prodrug to fluorouracil which is a thymidylate synthase inhibitor.<ref name = MD/>

Pharmacokinetics[edit]

Tegafur is metabolized into fluorouracil by CYP2A6.<ref>Nakayama, T,

 Therapeutic usefulness of postoperative adjuvant chemotherapy with Tegafur-Uracil (UFT) in patients with breast cancer: focus on the results of clinical studies in Japan., 
 The Oncologist, 
 
 Vol. 15(Issue: 1),
 pp. 26-36,
 DOI: 10.1634/theoncologist.2009-0255,
 PMID: 20080863,
 PMC: 3227888,
 
 Full text,</ref><ref>Matt, P, 
 The European Medicines Agency review of Tegafur/Gimeracil/Oteracil (Teysuno™) for the treatment of advanced gastric cancer when given in combination with cisplatin: summary of the Scientific Assessment of the Committee for medicinal products for human use (CHMP)., 
 The Oncologist, 
 
 Vol. 16(Issue: 10),
 pp. 1451-1457,
 DOI: 10.1634/theoncologist.2011-0224,
 PMID: 21963999,
 PMC: 3228070,
 
 Full text,</ref>

Adverse Effects[edit]

The major side effects of tegafur are similar to fluorouracil and include myelosuppression, central neurotoxicity, and gastrointestinal toxicity (especially diarrhea).<ref name = MD/> Gastrointestinal toxicity is the dose-limiting side effect of tegafur.<ref name = MD/> Central neurotoxicity is more common with tegafur than with fluorouracil.<ref name = MD/>

Interactive Pathway Map[edit]

Click on genes, proteins and metabolites below to link to respective articles.<ref name="WikiPathways" group="§">The interactive pathway map can be edited at WikiPathways:

FluoropyrimidineActivity_WP1601(link). {{{website}}}.

</ref>

[[File:

[[

]]

[[

]]

[[

]]

[[

]]

[[

]]

[[

]]

[[

]]

[[

]]

[[

]]

[[

]]

[[

]]

[[

]]

[[

]]

[[

]]

[[

]]

[[

]]

[[

]]

[[

]]

[[

]]

[[

]]

[[

]]

[[

]]

[[

]]

[[

]]

[[

]]

[[

]]

[[

]]

[[

]]

[[

]]

[[

]]

[[

]]

[[

]]

[[

]]

[[

]]

[[

]]

[[

]]

[[

]]

[[

]]

[[

]]

[[

]]

[[

]]

[[

]]

[[

]]

[[

]]

[[

]]

[[

]]

[[

]]

|{{{bSize}}}px|alt=Fluorouracil (5-FU) Activity edit]]

Fluorouracil (5-FU) Activity edit

Conclusion[edit]

Tegafur is a crucial chemotherapeutic agent used in the treatment of various cancers. Its effectiveness often relies on combination with other drugs that modulate its bioavailability and toxicity. Understanding its pharmacokinetics, mechanisms of action, and potential adverse effects is essential for healthcare professionals in oncology to optimize patient care and improve treatment outcomes.

References[edit]

This article is a medical stub. You can help WikiMD by expanding it!
Most recent articles Ongoing trials	Wikipedia

Navigation: Wellness - Encyclopedia - Health topics - Disease Index‏‎ - Drugs - World Directory - Gray's Anatomy - Keto diet - Recipes

Ad. Transform your health with W8MD Weight Loss, Sleep & MedSpa

Tired of being overweight?

Special offer:

Budget GLP-1 weight loss medications

Semaglutide starting from $29.99/week and up with insurance for visit of $59.99 and up per week self pay.
Tirzepatide starting from $45.00/week and up (dose dependent) or $69.99/week and up self pay

✔ Same-week appointments, evenings & weekends

Learn more:

Advertise on WikiMD

WikiMD Medical Encyclopedia

Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.

Translate this page: - East Asian 中文, 日本, 한국어, South Asian हिन्दी, தமிழ், తెలుగు, Urdu, ಕನ್ನಡ, Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, বাংলা
European español, Deutsch, français, Greek, português do Brasil, polski, română, русский, Nederlands, norsk, svenska, suomi, Italian
Middle Eastern & African عربى, Turkish, Persian, Hebrew, Afrikaans, isiZulu, Kiswahili,
Other Bulgarian, Hungarian, Czech, Swedish, മലയാളം, मराठी, ਪੰਜਾਬੀ, ગુજરાતી, Portuguese, Ukrainian

Tegafur